Cyclandelate
Structural formula | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Structural formula without stereochemistry | |||||||||||||||||||
General | |||||||||||||||||||
Non-proprietary name | Cyclandelate | ||||||||||||||||||
other names |
(3,3,5-trimethylcyclohexyl) -2-hydroxy-2-phenyl acetate ( IUPAC ) |
||||||||||||||||||
Molecular formula | C 17 H 24 O 3 | ||||||||||||||||||
Brief description |
white, amorphous solid |
||||||||||||||||||
External identifiers / databases | |||||||||||||||||||
|
|||||||||||||||||||
Drug information | |||||||||||||||||||
ATC code | |||||||||||||||||||
Drug class | |||||||||||||||||||
Mechanism of action | |||||||||||||||||||
properties | |||||||||||||||||||
Molar mass | 276.37 g · mol -1 | ||||||||||||||||||
Physical state |
firmly |
||||||||||||||||||
Melting point |
55-56.5 ° C |
||||||||||||||||||
boiling point |
192-194 ° C (1.82 kPa) |
||||||||||||||||||
Sublimation point |
20 ° C |
||||||||||||||||||
safety instructions | |||||||||||||||||||
|
|||||||||||||||||||
Toxicological data | |||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Cyclandelate is a drug that is used to treat cerebral and peripheral circulatory disorders . The antidementia “inhibits the influx of calcium from the blood into the red blood cells ( erythrocytes ), into the blood platelets ( thrombocytes ) and into the vascular wall muscles”. The drug acts as a vasodilator ( vasodilator ) by directly on the smooth muscle of blood vessels acts and can relax the vessel wall. Furthermore, the flow properties of the blood are improved by an increase in the elasticity of the red blood cells and also a decrease in the tendency of the blood platelets to clump and thus also a reduction in clot formation.
Cyclandelate can be used, among other things, to treat dementia ( nootropic ) and for interval therapy in migraines .
It was available in Switzerland under the trade name Cyclandelat Streuli until mid-2013, when the manufacturer stopped production. In Germany, Cyclandelat was withdrawn from the market on May 31, 2008 because the "fictitious approval of Natil capsules " was no longer valid and they were therefore no longer marketable . The reason given by the German manufacturer hotline at the time is the high costs of an approval extension as part of the approval process and for the required clinical tests .
Individual evidence
- ↑ a b c d Entry on cyclandelate. In: Römpp Online . Georg Thieme Verlag, accessed on May 30, 2014.
- ^ The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 452, ISBN 978-0-911910-00-1 .
- ↑ harmonized classification for this substance . A labeling of cyclandelates in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on December 28, 2019, is shown, which is derived from a self-classification by the distributor . There is not yet a
- ↑ How cyclandelate works
- ↑ Page no longer available , search in web archives: product range card (PDF; 532 kB)
- ↑ DrugBase Online for Natil capsules
literature
- Andreas Ruß: Medicines pocket 2008 . 13th edition. Börm Bruckmeier, Grünwald 2007, p. 235.